Table 1 Clinical Characteristics of the Subjects.

From: Review of the Long-term Effects of Autologous Bone-Marrow Mononuclear Cell Implantation on Clinical Outcomes in Patients with Critical Limb Ischemia

Variable

Historical control

(n = 20)

BM-MNC implantation

(n = 30)

P value

Age, yr

65.4 ± 10.2

67.2 ± 9.2

0.51

Gender, men/women

16/4

19/11

0.35

Body mass index, kg/m2

23.8 ± 4.1

22.0 ± 3.5

0.11

Rutherford category, n (%)

  

N.A.

3

0 (0)

1 (3)

 

4

1 (5)

9 (30)

 

5

10 (50)

15 (50)

 

6

9 (45)

5 (17)

 

Medical history, n (%)

   Hypertension

19 (95)

26 (87)

0.64

   Dyslipidemia

10 (50)

18 (60)

0.57

   Diabetes mellitus

19 (95)

25 (83)

0.38

   Previous myocardial infarction

12 (60)

15 (50)

0.57

   Previous stroke

7 (35)

8 (27)

0.55

   Chronic kidney disease

13 (65)

14 (47)

0.25

   Hemodialysis

9 (45)

8 (27)

0.23

   Smoker (pre)

15 (75)

13 (43)

0.04

Medications, n(%)

   Anti-coagulant

6 (30)

11 (37)

0.76

   Anti-platelets

16 (80)

24 (80)

1.00

   ACE inhibitors

1 (5)

5 (17)

0.38

   ARBs

7 (35)

12 (40)

0.77

   Calcium-channel blockers

5 (25)

13 (43)

0.24

   Statins

8 (40)

7 (23)

0.23

   Sulfonylurea/metformin/other

9 (45)

11 (37)

0.57

   Insulin

10 (50)

6 (20)

0.03

  1. BM-MNC indicates bone-marrow mononuclear cell; ACE, Angiotensin-converting enzyme; ARB, Angiotensin II receptor blocker.